/clinical/,/clinical/cckm-tools/,/clinical/cckm-tools/content/,/clinical/cckm-tools/content/beacon-protocols/,/clinical/cckm-tools/content/beacon-protocols/supportive-care/,

/clinical/cckm-tools/content/beacon-protocols/supportive-care/name-122970-en.cckm

201711331

page

100

UWHC,UWMF,

Tools,

Clinical Hub,UW Health Clinical Tool Search,UW Health Clinical Tool Search,Beacon Protocols,Supportive Care

CSC SC Rasburicase Ver 11-20-17 (HL 5800)

CSC SC Rasburicase Ver 11-20-17 (HL 5800) - Clinical Hub, UW Health Clinical Tool Search, UW Health Clinical Tool Search, Beacon Protocols, Supportive Care


CSC SC RASBURICASE VER: 11-20-17 –  Properties
Cycle 1 –  11/22/2017 through 11/23/2017 (2 days), Planned
Day 1, Cycle 1 –  Planned for 11/22/2017
Additional Labs
URIC ACID FOR PATIENTS ON RASBURICASE
Expected: S Approximate, Expires: S+122, Routine
Monitor Uric Acid at baseline, every 8 hours until stable then every 12 to 24 hours.
Pre-Labs
SODIUM
Expected: S Approximate, Expires: S+365, Routine
POTASSIUM
Expected: S Approximate, Expires: S+365, Routine
CHLORIDE
Expected: S Approximate, Expires: S+365, Routine
CARBON DIOXIDE
Expected: S Approximate, Expires: S+365, Routine
CALCIUM
Expected: S Approximate, Expires: S+365, Routine
MAGNESIUM
Expected: S Approximate, Expires: S+365, Routine
PHOSPHATE
Expected: S Approximate, Expires: S+365, Routine
CREATININE
Expected: S Approximate, Expires: S+365, Routine
BUN
Expected: S Approximate, Expires: S+365, Routine
Hydration
sodium chloride 0.9 % infusion
Intravenous, CONTINUOUS Starting when released Until Discontinued
Administer 2 to 3 L/m2/day IV to maintain urine output at 80 to 100 mL/m2/hour.
Treatment Medications
rasburicase (ELITEK) 3 mg in sodium chloride 0.9 % 50 mL bag/syringe
3 mg, Intravenous, ONCE, 1 dose Starting when released
INITIAL DOSE. Maximum of 3 mg.
Round dose to the nearest vial size (1.5 mg, 3 mg or 6 mg).
Take Home Medications
allopurinol (ZYLOPRIM) 300 MG tab
Take 1 tab by mouth one time daily., 300 mg, R-0, 1 X DAILY starting S, Local Printer
Day 2 - Second Dose for Use in Limited Patients Only, Cycle 1 –  Planned for 11/23/2017
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
ZZtestonc,Andrew [2428787]
11/22/2017 12:25:37 PM Page 1 of 2
Copyright © 2017 University of Wisconsin Hospitals and Clinics Authority
Contact: Lee Vermeulen, CCKM@uwhealth.org Last Revised:
 
11/2017CCKM@uwhealth.org

Other
Note to All Staff (1)
Repeat dosing of rasburicase is indicated in only a certain limited number of patients. Criteria for second dose are:  24
to 48 hours should have passed since 1st dose AND uric acid level is increasing OR uric acid level is greater than 8
mg/dL.
Additional Labs
URIC ACID FOR PATIENTS ON RASBURICASE
Expected: S Approximate, Expires: S+122, Routine
Monitor Uric Acid at baseline, every 8 hours until stable then every 12 to 24 hours.
Pre-Labs
SODIUM
Expected: S Approximate, Expires: S+365, Routine
POTASSIUM
Expected: S Approximate, Expires: S+365, Routine
CHLORIDE
Expected: S Approximate, Expires: S+365, Routine
CARBON DIOXIDE
Expected: S Approximate, Expires: S+365, Routine
CALCIUM
Expected: S Approximate, Expires: S+365, Routine
MAGNESIUM
Expected: S Approximate, Expires: S+365, Routine
PHOSPHATE
Expected: S Approximate, Expires: S+365, Routine
CREATININE
Expected: S Approximate, Expires: S+365, Routine
BUN
Expected: S Approximate, Expires: S+365, Routine
Hydration
sodium chloride 0.9 % infusion
Intravenous, CONTINUOUS Starting when released Until Discontinued
Administer 2 to 3 L/m2/day IV to maintain urine output at 80 to 100 mL/m2/hour.
Treatment Medications
rasburicase (ELITEK) 0.15 mg/kg in sodium chloride 0.9 % 50 mL bag/syringe
0.15 mg/kg, Intravenous, ONCE, 1 dose Starting when released
SECOND DOSE INDICATED NO SOONER THAN 24 TO 48 HOURS AFTER INITIAL DOSE ONLY IF  URIC ACID LEVEL IS
INCREASING OR URIC ACID IS GREATER THAN 8 MG/DL. Maximum dose 6 mg.
Round dose to the nearest vial size (1.5 mg, 3 mg or 6 mg).
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
ZZtestonc,Andrew [2428787]
11/22/2017 12:25:37 PM Page 2 of 2
Copyright © 2017 University of Wisconsin Hospitals and Clinics Authority
Contact: Lee Vermeulen, CCKM@uwhealth.org Last Revised: 11/2017CCKM@uwhealth.org